Urolithiasis: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
{{TOC|right}} | |||
In [[medicine]], '''urolithiasis''' if the "formation of [[Calculus (medicine)|stones]] in any part of the [[urinary tract]], usually in the [[kidney]]; [[urinary bladder]]; or the [[ureter]]."<ref>{{MeSH}}</ref> | In [[medicine]], '''urolithiasis''' if the "formation of [[Calculus (medicine)|stones]] in any part of the [[urinary tract]], usually in the [[kidney]]; [[urinary bladder]]; or the [[ureter]]."<ref>{{MeSH}}</ref> | ||
Revision as of 00:32, 13 June 2010
In medicine, urolithiasis if the "formation of stones in any part of the urinary tract, usually in the kidney; urinary bladder; or the ureter."[1]
Classification
Etiology/cause
- Hypercalcuria - >140 mg/gm of urine creatinine or >4 mg/kg of body weight
- Hyperoxaluria - >40mg in 24 hour urine. May be primary or secondary to disorders such as inflammatory bowel disease
- Hypocitruria
- Uric acid
- Struvite
- Cysteine
Treatment
Prevention
Chlorthalidone reduces recurrence of calcium oxalate stones.[2][3]
References
- ↑ Anonymous (2024), Urolithiasis (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Ettinger B, Citron JT, Livermore B, Dolman LI (1988). "Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.". J Urol 139 (4): 679-84. PMID 3280829.
- ↑ Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I Figuls M (2009). "Pharmacological interventions for preventing complications in idiopathic hypercalciuria.". Cochrane Database Syst Rev (1): CD004754. DOI:10.1002/14651858.CD004754.pub2. PMID 19160242. Research Blogging.